<DOC>
	<DOC>NCT03055143</DOC>
	<brief_summary>This was a randomized, multi centre, open label, two treatment, two period, two sequence, single dose, crossover study, with at least 28 days washout between doses, conducted under fed (normal breakfast) conditions.</brief_summary>
	<brief_title>Study of Doxorubicin in Patients With Metastatic Breast Cancer/Advanced Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>1. Availability of volunteer for the entire study period and willingness to adhere to protocol requirements as evidenced by written informed consent. 2. Patients with metastatic breast cancer/advanced ovarian cancer having age within the range of between 1855 years. 3. Subjects who had no evidence of underlying disease 4. Subjects who had signed written consent form 1. Females who were pregnant, breastfeeding, or are likely to become pregnant 2. Subjects who had any medical condition (except metastatic breast cancer/advanced ovarian cancer) that could jeopardize their health or prejudice the results 3. Subjects deemed uncooperative or noncompliant 4. Smoking or consumption of any nicotine products</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>